To the editor:

Long-acting suspensions of buprenorphine may combine management and medical approaches to reduce adverse effects associated with buprenorphine analgesia. Extended-release drugs reduce the animal\'s exposure to cycles of hyper- and hypo-therapeutic drug levels. They also reduce the opportunity for iatrogenic injuries associated with efforts to secure small animals for repeated drug injections. A single injection of these drugs provides the animal with two to three days of analgesic therapy, and can be given when the animal is still under post-surgical anesthesia support^[@CR1],[@CR2],[@CR3],[@CR4]^. However, the effects of long-acting buprenorphine analgesics on the risks of nausea in rats remain uncertain.

We previously conducted Target Animal Safety (TAS) tests of a lipid-bound, extended-release buprenorphine suspension in Fischer rats^[@CR2]^. Safety trials for new veterinary pharmaceutical products require clinical and histopathology studies of male and female animals given up to tenfold excess doses of the drug. Our tests included trials using a single injection with increasing concentrations of buprenorphine, and three repeat injections at four-day intervals with increasing concentrations of buprenorphine. The tests included blinded behavioral observations to monitor unexpected signs of stress and pain. Because we avoided the use of hardwood bedding, nausea-induced gastric distress and pica were not expected. We did not find significant weight losses. However, we observed nausea-related behaviors consisting of excessive self-licking and gnawing in both the single and repeat dose-escalation trials.

The objective of this study was to measure the incidence, duration, and characteristics of nausea behavior in rats treated with an extended-release buprenorphine analgesic and maintained on soft fiber bedding. We monitored signs of nausea in a trial using 18 female Fischer F344/NTac rats weighing 170--180 g obtained from Taconic Farms (Hudson, NY). The study used three groups of six rats: two groups of drug-treated rats and one group with the drug-free vehicle as a control to investigate the effects of the drug on nausea-related behavioral signs. Guidelines for TAS studies specify a minimum number of three animals per group. Four rats were used in TAS studies to account for potential morbidity during jugular vein phlebotomy. Because there is limited information about the side effects of nausea associated with extended-release buprenorphine, we used six rats per group in the present tests to increase the potential to observe side effects.

Rats were housed in an environmentally-controlled room maintained at 68 to 79° F, a relative humidity of 30 to 70% and with a 12-h light/12-h dark cycle. Rats were housed two to three per cage during the quarantine and acclimation period in ventilated micro isolator cages; they were housed two per cage during the study period. Cages were changed daily for the first seven days of the study to prevent re-dosing by coprophagy. Carefresh Natural bedding (Ferndale, WA) was used to absorb liquids. The rats were provided *ad libitum* access to drinking water (Baltimore City Water System, Baltimore, MD) and Harlan TEKLAD Certified Global Rodent Diet 2016C (Harlan TEKLAD, Indianapolis, IN). Health surveillance was conducted by a soiled-bedding sentinel system. Rats were considered negative for pneumonia virus of mice, reovirus, Sendai virus, lymphocytic choriomeningitis virus, rat coronavirus, sialodacryoadenitis virus, rat parvovirus, Kilham rat virus, Toolan H1 parvovirus, rat theilovirus, cilia-associated respiratory bacillus, *Pneumocysti carinii, Mycoplasma pulmonis* and pinworms. The rats were quarantined and acclimated for six days before dosing. A clinical veterinarian approved the animals for study use and all rats appeared normal with no signs of disease. Animals were weighed before assignment to the dose groups to assure the weight of each rat was within 10% of the group average. The order of dosing started with the 1.3 mg/kg group and ended with the vehicle control group.

Rats were given a vehicle control, 0.0 mg/kg buprenorphine, the intended dose of 0.65 mg/kg of buprenorphine, and a twofold excess dose of 1.3 mg/kg buprenorphine. The control suspension consisted of cholesterol and glycerol tristearate (96:4) suspended in a medium-chain triglyceride oil (8 mg/100 uL). The drug suspension consisting of buprenorphine, cholesterol, and glycerol tristearate, trade name Animalgesics for Mice, was supplied by Animalgesics Labs (Millersville, MD). Procedures were done in a ventilated hood in the animal room containing the rat cages. Because of its ease of use and history of safety in our laboratories, we anesthetized rats with 0.65 mL of an intraperitoneal (IP) solution containing 25 mg/mL ketamine hydrochloride, 2.5 mg/mL xylazine, and 14.25% ethyl alcohol in saline. At approximately 7:00 a.m. we then injected the rats once subcutaneously with the designated dose of test article or buprenorphine-free control suspension in the mid-dorsal area using a 22 G needle attached to a 1 mL syringe. Rats were anesthetized and dosed in approximately 45 min. Following dose administration, we transferred the rats to a recovery cage on a heating pad until recovered. Once the animal regained consciousness, demonstrated normal movement and the absence of signs of distress, we returned it to its home cage. The tail of each animal was marked with a sharpie pen to denote the animal number in the group.

During the first week of this study, animals were observed at the cage level once daily at approximately 9:00 a.m. for morbidity, mortality, signs of toxicity (abnormal respiration, tremors, ocular discharge, facial signs, posture, and movement) and overall appearance. Rats received "hands-on" detailed clinical observations once daily after 2:00 p.m. for abnormal clinical signs (ocular discharge, motor activity, signs of pain or distress, etc.). Paw gnawing and excess grooming were scored on a yes-no basis. Rats were observed weekly thereafter. The observer, a female veterinarian, was blind to the treatment group. The experimental unit was the single animal.

To extend the baseline data on nausea-related behavior associated with buprenorphine analgesia, we compared the data from this study with the results from the 64 rats in the previous two TAS trials^[@CR2]^. The plasma drug concentrations reported here were collected in the TAS study^[@CR2]^. Rat blood samples were obtained from technician-restrained, un-anesthetized animals by jugular vein phlebotomy. Samples were collected at 6, 24, 48, 72, and 96 h after the drug injection. The zero time samples were collected 24 h before the rats were dosed with drug. The plasma samples were analyzed by a Shimadzu LC-20AD mass spectrometer (Columbia MD). The sensitivity of the assay was 0.5 ng/mL^[@CR1]^.

We did not observe pica in the present study. All rats survived until the pre-determined endpoint of the study at one year with no observed abnormalities. The majority of rats in both treatment groups did not exhibit behavior indicative of nausea during either the morning or afternoon observation periods ([Table 1](#Tab1){ref-type="table"}). We did find that 1 of 6 (17%) rats dosed with 0.65 mg/kg of lipid-bound buprenorphine and 2 of 6 rats (34%) dosed with 1.3 mg/kg of the drug showed signs of nausea, including excess grooming and self-gnawing. The time of nausea onset was between 24 and 48 h and lasted three to four days. By day 4, the behavior of the single affected female in the intended dose group was unremarkable. By day five, the behavior of the two affected rats in the higher dose group also was within normal limits.Table 1Cumulative incidence of nausea per dose, female F344/NTac ratsBuprenorphine dose (mg per kg body weight)Number of ratsDay 1Day 2Day 3Day 4Day 5-706 female000000.656 female111001.36 female12220

Blood level concentrations of the drug poorly correlate with the appearance of the nausea signs. Following a single subcutaneous (SC) dose of 0.65 mg/kg, the plasma concentrations of buprenorphine ranged from 1 ng/mL at 6 h to 0.7 ng/mL at day three. Drug levels in the group dosed with 1.3 mg/kg ranged from 5 ng/mL at 6 h post injection to 7 ng/mL at day three. Opioid binding properties of buprenorphine may account for lack of coordination between nausea signs and blood concentrations of drug. Buprenorphine plasma concentrations greater than 0.75 ng/mL have demonstrated clinically relevant analgesia in laboratory animals and humans^[@CR5],[@CR6]^. Despite having applicable blood concentrations of drug for at least three days, plasma levels of buprenorphine were not closely coupled with the appearance or the duration of nausea-related behavior.

These data are consonant with the results of our TAS study, which showed excessive grooming and self-gnawing of the forepaw in 6 of 24 (25%) rats in a single injection trial. Nausea-related behavior was seen in 4 of 24 (17%) rats in the second trial of the extended-release buprenorphine suspension^[@CR2]^. The incidence of the behavior was highest in animals receiving 1.3 mg/kg, twice the intended dose. The onset of the behavior in all studies was generally within the first day of dosing. Yet delayed onset commonly was observed. In the present study, one rat exhibited the behavior on day 2. In the first TAS Trial, 5 of 24 (21%) drug-treated rats did not exhibit signs until day two or three. In the second TAS trial, 2 of 24 (8%) of the drug-treated rats had latencies through day three ([Table 2](#Tab2){ref-type="table"}).Table 2Cumulative incidence of nausea in TAS trials**TAS Trial 1Buprenorphine dose (mg per kg body weight)Number of ratsDay 1Day 2Day 3Day 4**08 (4 male, 4 female)000^\*\*^1.38 (4 male, 4 female)01 female3 (2 female, 1 male)^\*\*^3.98 (4 male, 4 female)1 male2 (1 male, 1 female)1 female^\*\*^6.58 (4 male, 4 female)002 (1 male, 1 female)^\*\*^**TAS Trial 2Buprenorphine dose (mg per kg body weight)Number of ratsDay 1Day 2Day 3Day 4**08 (4 male, 4 female)00001.38 (4 male, 4 female)1 male1 male1 male3 (2 male, 1 female)3.98 (4 male, 4 female)1 female1 female1 female06.58 (4 male, 4 female)0000^\*\*^Rats in TAS Trial 1 were removed on Day 4 without clinical observations.

Since the early reports by Clark *et al*.^[@CR7]^ and Bender^[@CR8]^ describing lethal consequences of buprenorphine-induced pica in rats, buprenorphine analgesia has been regarded with caution in research with laboratory rat models of human disease. Subsequent reports that the dangers of pica can be managed with appropriate husbandry are confirmed in the present study. Although further studies are needed regarding the safe use of buprenorphine analgesics in other strains of rat, the data in this study extend data reviewed by Foley^[@CR6]^ and Guarnieri *et al*.^[@CR5]^ demonstrate a high safety index for buprenorphine in laboratory animal medicine. More work also is needed regarding the incidence and severity side effects from buprenorphine analgesia delivered as a food ingredient, and in polymer and gel-bound suspensions.

The consensus is that rats can be treated safely with acute doses and extended-release buprenorphine analgesia provided the rats are allowed to recover on paper or soft bedding. Nonetheless, because hardwood bedding is a standard in many facilities, more information is needed about the duration of nausea with different strains, sex, analgesics, and procedures to allow the safe return of the rats to such standard husbandry condition^[@CR9],[@CR10],[@CR11]^.
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